On April 20, Zhifei bio (300122) released the first quarter report of 2021. During the reporting period, the company achieved an operating revenue of 3926600928.88 yuan, up 49.04% year on year; the net profit attributable to shareholders of listed companies was 938179113.58 yuan, up 81.69% year on year.
During the reporting period, the net cash flow from operating activities was -113803717.67 yuan, and the net assets attributable to shareholders of listed companies were 9186843572.85 yuan by the end of 2020.
During the reporting period, the operating revenue was 3926600928.88 yuan, a year-on-year increase of 49.04%, which was mainly due to the increase of sales scale and the growth of independent products and agency products.
The total profit turned from loss to profit on a year-on-year basis, mainly due to the large growth of sales of independent products and agency products in the current period, resulting in the growth of total profit.
According to digbei.com, Zhifei biology is mainly engaged in the research and development, production, sales, promotion, distribution, import and export of vaccines and biological products.